Initial assessment of safety and clinical feasibility of irreversible electroporation in the focal treatment of prostate cancer

Prostate Cancer and Prostatic Diseases

Volumn 17, Issue 4, 2014, Pages 343-347

  Valerio, M ^a,b,c   Stricker, P D ^d   Ahmed, H U ^a,b   Dickinson, L ^a,b   Ponsky, L ^d,e   Shnier, R ^d   Allen, C ^b   Emberton, M ^a,b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^d St Vincent's Prostate Cancer Centre   (Australia)

^e UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; PROSTATE SPECIFIC ANTIGEN;

ABLATION THERAPY; AGED; ARTICLE; CLINICAL ARTICLE; DYSURIA; ELECTRODE; ELECTROPORATION; FEASIBILITY STUDY; FOCAL IRREVERSIBLE ELECTROPORATION; HEMATURIA; HIGH INTENSITY FOCUSED ULTRASOUND; HUMAN; IRREVERSIBLE ELECTROPORATION DEVICE; MALE; MEDICAL DEVICE COMPLICATION; MINIMAL RESIDUAL DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT SAFETY; PROSTATE CANCER; PROSTATECTOMY; RECTOURETHRAL FISTULA; RETROSPECTIVE STUDY; TACHYCARDIA; TRANSRECTAL ULTRASONOGRAPHY; URETHRA FISTULA; URETHRA STRICTURE; URINARY TRACT INFECTION; URINE RETENTION; UROGENITAL TRACT DISEASE; ADVERSE EFFECTS; ELECTROCHEMOTHERAPY; MIDDLE AGED; PATHOLOGY; PROCEDURES; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

AGED; ELECTROCHEMOTHERAPY; FEASIBILITY STUDIES; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84908873700     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2014.33     Document Type: Article

References (29)

1. Wilt TJ, Brawer MK, Jones KM, Barry MJ, Aronson WJ, Fox S et al. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 2012; 367: 203-213.
2. Ahmed HU, Freeman A, Kirkham A, Sahu M, Scott R, Allen C et al. Focal therapy for localized prostate cancer: a phase I/II trial. J Urol 2011; 185: 1246-1254.
3. Ahmed HU, Hindley RG, Dickinson L, Freeman A, Kirkham AP, Sahu M et al. Focal therapy for localised unifocal and multifocal prostate cancer: a prospective development study. Lancet Oncol 2012; 13: 622-632.
4. ® soluble for localised prostate cancer compared to active surveillance. ClinicalTrials.gov Identifier: NCT01310894, 31 October 2012.
5. Bahn D, de Castro Abreu AL, Gill IS, Hung AJ, Silverman P, Gross ME et al. Focal cryotherapy for clinically unilateral, low-intermediate risk prostate cancer in 73 men with a median follow-up of 3.7 years. Eur Urol 2012; 62: 55-63.
6. Oto A, Sethi I, Karczmar G, McNichols R, Ivancevic MK, Stadler WM et al. MR imaging-guided focal laser ablation for prostate cancer: phase I trial. Radiology 2013; 267: 932-940.
7. Barret E, Ahallal Y, Sanchez-Salas R, Galiano M, Cosset JM, Validire P et al. Morbidity of focal therapy in the treatment of localized prostate cancer. Eur Urol 2013; 63: 618-622.
8. Lindner U, Weersink RA, Haider MA, Gertner MR, Davidson SR, Atri M et al. Image guided photothermal focal therapy for localized prostate cancer: phase I trial. J Urol 2009; 182: 1371-1377.
9. Valerio M, Ahmed HU, Emberton M, Lawrentschuk N, Lazzeri M, Montironi R et al. The role of focal therapy in the management of localised prostate cancer: a systematic review. Eur Urol 2013; S0302-2838: 00557-5.
10. Pech M, Janitzky A, Wendler JJ, Strang C, Blaschke S, Dudeck O et al. Irreversible electroporation of renal cell carcinoma: a first-in-man phase I clinical study. Car-diovasc Intervent Radiol 2011; 34: 132-138.
11. Martin RC 2nd, McFarland K, Ellis S, Velanovich V. Irreversible electroporation therapy in the management of locally advanced pancreatic adenocarcinoma. J A Coll Surg 2012; 215: 361-369.
12. Charpentier KP. Irreversible electroporation for the ablation of liver tumors: are we there yet? Arch Surg 2012; 147: 1053-1061.
13. Philips P, Hays D, Martin RC. Irreversible electroporation ablation (IRE) of unre-sectable soft tissue tumors: learning curve evaluation in the first 150 patients treated. PloS One 2013; 8: e76260.
14. Onik G, Rubinsky B. Irreversible Electroporation: First Patient Experience Focal Therapy of Prostate Cancer. Series in Biomedical Engineering. Berlin Heidelberg: Springer, 2010, pp 235-247.
15. Neal RE 2nd, Millar JL, Kavnoudias H, Royce P, Rosenfeldt F, Pham A et al. In vivo characterization and numerical simulation of prostate properties for non-thermal irreversible electroporation ablation. Prostate 2014; 74: 458-468.
16. Rubinsky J, Onik G, Mikus P, Rubinsky B. Optimal parameters for the destruction of prostate cancer using irreversible electroporation. J Urol 2008; 180: 2668-2674.
17. Faroja M, Ahmed M, Appelbaum L, Ben-David E, Moussa M, Sosna J et al. Irreversible electroporation ablation: is all the damage nonthermal? Radiology 2013; 266: 462-470.
18. Emberton M. A prospective development study evaluating focal therapy using irreversible electroporation (Nanoknife®) in men with localised prostate cancer. ClinicalTrials.gov Identifier: NCT01726894, 31 October 2012.
19. Punwani S, Emberton M, Walkden M, Sohaib A, Freeman A, Ahmed H et al. Pro-static cancer surveillance following whole-gland high-intensity focused ultrasound: comparison of MRI and prostate-specific antigen for detection of residual or recurrent disease. Bri J Radiol 2012; 85: 720-728.
20. Gupta RT, Kauffman CR, Polascik TJ, Taneja SS, Rosenkrantz AB. The state of prostate MRI in 2013. Oncology (Williston Park) 2013; 27: 262-270.
21. Turkbey B, Choyke PL. Multiparametric MRI and prostate cancer diagnosis and risk stratification. Curr Opin Urol 2012; 22: 310-315.
22. Arumainayagam N, Ahmed HU, Moore CM, Freeman A, Allen C, Sohaib SA et al. Multiparametric MR imaging for detection of clinically significant prostate cancer: a validation cohort study with transperineal template prostate mapping as the reference standard. Radiology 2013; 268: 761-769.
23. Thompson JE, Moses D, Shnier R, Brenner P, Delprado W, Ponsky Let al. Multiparametric magnetic resonance imaging guided diagnostic biopsy detects significant prostate cancer and could reduce unnecessary biopsies and over detection: a prospective study. J Urol (e-pub ahead of print 8 February 2014; doi: 10.1016/j.juro.2014.01.014.
24. Onik G, Mikus P, Rubinsky B. Irreversible electroporation: implications for prostate ablation. Technol Cancer Res Treat 2007; 6: 295-300.
25. Li W, Fan Q, Ji Z, Qiu X, Li Z. The effects of irreversible electroporation (IRE) on nerves. PloS One 2011; 6: e18831.
26. Tsivian M, Polascik TJ. Bilateral focal ablation of prostate tissue using low-energy direct current (LEDC): a preclinical canine study. BJU Int 2013; 112: 526-530.
27. McCulloch P, Cook JA, Altman DG, Heneghan C, Diener MK. IDEAL framework for surgical innovation 1: the idea and development stages. BMJ 2013; 346: f3012.
28. Ergina PL, Barkun JS, McCulloch P, Cook JA, Altman DG. IDEAL framework for surgical innovation 2: observational studies in the exploration and assessment stages. BMJ 2013; 346: f3011.
29. Cook JA, McCulloch P, Blazeby JM, Beard DJ, Marinac-Dabic D, Sedrakyan A. IDEAL framework for surgical innovation 3: randomised controlled trials in the assessment stage and evaluations in the long term study stage. BMJ 2013; 346: f2820.